The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
about
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study.Capecitabine plus paclitaxel induction treatment in gastric cancer patients with liver metastasis: a prospective, uncontrolled, open-label Phase II clinical study.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
P2860
The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@en
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@nl
type
label
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@en
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@nl
prefLabel
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@en
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@nl
P2093
P1433
P1476
The multicenter, phase II pros ...... in advanced gastric carcinoma.
@en
P2093
Chunmei Bai
Fengchun Zhang
Guoqing Hu
Jifang Gong
Jinwan Wang
Leizhen Zheng
P304
P356
10.1634/THEONCOLOGIST.2013-0137
P577
2014-01-23T00:00:00Z